NVAX Stock – Here’s What You Need to Know About COVID Variants’ Impact on Vaccine Efficacy
The more widely a virus is circulating in a population and infecting individuals, the more likely it is that the virus will mutate, according to the Centers for Disease Control and Prevention (CDC). Over a year into the global coronavirus pandemic, we face an increasing number of variants of the virus, and the fear that our methods of prevention and treatment might not stack up against the more transmissible and potentially more dangerous strains originating in South Africa, Brazil, and the UK.
We now have data from Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) on how their vaccines perform against these new strains — here’s what that new data means, and some good news on the ability of shots to provide protection.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Fintech Zoom premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.